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Schizophrenia is a heritable complex phenotype associated with a background risk involving 
multiple common genetic variants of small effect and a multitude of environmental exposures. 
Early twin and family studies using proxy-genetic liability measures suggest gene-environment 
interaction in the etiology of schizophrenia spectrum disorders, but the molecular evidence is 
scarce. Here, by analyzing the main and joint associations of polygenic risk score for 
schizophrenia (PRS-SCZ) and environmental exposures in 1,699 patients with a diagnosis of 
schizophrenia spectrum disorders and 1,542 unrelated controls with no lifetime history of a 
diagnosis of those disorders, we provide further evidence for gene-environment interaction in 
schizophrenia. Evidence was found for additive interaction of molecular genetic risk state for 
schizophrenia (binary mode of PRS-SCZ above 75% of the control distribution) with the 
presence of lifetime regular cannabis use and exposure to early-life adversities (sexual abuse, 
emotional abuse, emotional neglect, and bullying), but not with the presence of hearing 
impairment, season of birth (winter birth), and exposure to physical abuse or physical neglect 
in childhood. The sensitivity analyses replacing the a priori PRS-SCZ at 75% with alternative 
cut-points (50% and 25%) confirmed the additive interaction. Our results suggest that the 
etiopathogenesis of schizophrenia involves genetic underpinnings that act by making 
individuals more sensitive to the effects of some environmental exposures.   
 
Key words: Schizophrenia, psychosis, genetics, environment, gene-environment interaction, 
polygenic risk, childhood trauma, cannabis, bullying 
Schizophrenia is a complex phenotype characterized by reality distortion, cognitive 
alteration and negative symptoms. Although the prevalence of schizophrenia spectrum 
disorders is relatively low – approximately 0.47% for schizophrenia (the poor outcome 
fraction) and 3.0% for other clinical diagnoses of psychotic disorders1 – they account for a 
tremendous personal, economic and societal burden, with 218 disability adjusted life years 
(DALYs) per 100,0002, making schizophrenia the fifth leading cause of DALYs in the age 
group of 15-44 years. These figures indicate that there is an urgent need for breakthroughs in 
prevention, diagnosis and management of schizophrenia and related disorders, which can be 
achieved by increased understanding of etiopathology. 
Decades of work consistently yielding high heritability estimates document the role of 
genetic background in the etiopathology of these disorders3,4. In agreement with findings from 
early family-based studies, recent results from the Danish nationwide registers confirm that the 
heritability estimates range from 73% for schizophrenia spectrum disorders to 79% for narrow 
schizophrenia diagnosis5.  
Based on these findings from the field of quantitative genetic epidemiology, molecular 
genetics has emerged as arguably the most popular area of investigation in research targeting 
schizophrenia spectrum disorders. Easy and low-cost access to high-throughput techniques has 
increased genetic resolution. The Psychiatric Genomics Consortium6 was founded to achieve 
the power required to detect small effect sizes in a genome-wide association (GWA) analysis. 
The Schizophrenia Working Group of the Consortium identified 108 genome-wide significant 
loci7, and the number of novel genetic variants keeps growing as a function of sample size8. 
GWA findings, in line with the half-century-old polygenic theory of schizophrenia9, 
established that a large fraction of the genetic risk is explained by many common genetic 
variants with very small effects sizes.  
However, the proportion of the genetic liability accounted for by single nucleotide 
polymorphisms (SNPs) detected in current GWA arrays represents only a fraction of the effect 
that was suggested by heritability estimates from twin studies. In other terms, there is a large 
“heritability gap” between twin and molecular genetics studies10. The most likely explanation 
for this gap is that part of the genetic effect documented by twin studies is contingent on 
environmental factors shared by individuals growing up in the same family10. The etiology of 
psychosis spectrum disorder is likely to involve genetic underpinnings that act by making 
individuals more sensitive to the effects of environmental exposures or by driving individuals 
to higher exposure rates11.  
In parallel to the growing knowledge base in genetics, environmental research into 
schizophrenia has produced consistent findings over years. Observational studies have 
identified various exposures associated with risk of psychosis spectrum disorder at different 
levels of evidence, with varying magnitude of the effect size estimates. These environmental 
risk factors include cannabis use, childhood adversities (e.g., sexual abuse, emotional neglect), 
peer-bullying, urban environment, proxies of social exclusion (e.g., ethnic minority, 
immigration, and hearing impairment), season of birth, and obstetric and pregnancy 
complications12,13.  
Although findings from empirical investigations relying on surrogates of genetic risk (i.e., 
familial history of schizophrenia) argue for a strong influence of environment in moderating 
genetic vulnerability11, operationalizing and translating these findings by using molecular 
candidate-gene approaches have been challenging tasks14. 
The utilization of polygenic risk score (PRS) as a single metric of molecular genetic risk 
has considerably increased the power to detect associations with phenotypes as well as gene-
environment interactions. Currently, the PRS for schizophrenia (PRS-SCZ) of a subject can be 
estimated by summing the log odds ratios of individual SNPs multiplied by the number of risk 
alleles present at the corresponding loci15. PRS-SCZ has been shown to explain up to 7% of 
variation on the liability scale to schizophrenia, at least when using the latest release of the 
Psychiatric Genomics Consortium in patients with more chronic forms7.  
We recently discussed the challenges of evaluating the role of environmental exposures in 
psychiatry and the need to use exposure-wide systematic approaches to separate genuine strong 
signals from selective reporting16. Guided by this, we aimed to analyze the main and joint 
associations of environmental exposures and PRS-SCZ in a cross-sectional sample that was 
specifically collected to test for gene-environment interactions in schizophrenia.  
 
 
METHODS 
 
Study population 
 
This case-control gene-environment interaction study used data from the Work-package 6 
of the European Network of National Networks studying Gene-Environment Interactions in 
Schizophrenia (EUGEI)17 and the Genetic Risk and Outcome of Psychosis (GROUP) study18. 
Data were collected between 2010 and 2015 in the Netherlands, Turkey, Spain and Serbia.  
Patients were diagnosed with schizophrenia spectrum disorders according to the DSM-IV-
TR (average duration of illness since age of first contact with mental health services = 9.9 
years). The diagnosis was later confirmed by the Operational Criteria Checklist for Psychotic 
and Affective Illness19 in the EUGEI, and the Schedules for Clinical Assessment in 
Neuropsychiatry20 or the Comprehensive Assessment of Symptoms and History21 in the 
GROUP. Unrelated controls with no lifetime were recruited from the same population as the 
cases. Exclusion criteria for all participants were a diagnosis of psychotic disorder due to 
another medical condition, a history of head injury with loss of consciousness, and an 
intelligence quotient <70.  
A total of 1,866 patients and 1,583 healthy participants with genotype data available were 
included. As the predictive power of PRS-SCZ has not been established in people of non-white 
ethnic origin23, the present analyses were restricted to participants of Caucasian white ethnic 
origin. The final sample included 1,699 patients and 1,542 unrelated controls.  
The EUGEI and the GROUP projects were approved by the medical ethics committees of 
all participating sites and conducted in accordance with the Declaration of Helsinki. All 
respondents provided written informed consent. Participants below the age of 18 signed an 
assent; parent(s) also signed an informed consent. 
To achieve high quality and homogeneity in clinical, experimental and environmental 
assessments, standardized instruments were administered by psychiatrists, psychologists or 
trained research assistants who completed mandatory on-site training sessions and online 
training modules, including interactive interview videos and self-assessment tools17,18. Both 
on-site and online training sessions were repeated annually to maintain high inter-rater 
reliability throughout the study enrollment period.  
 
Environmental exposures 
 
Within the limits of data availability, we sought to examine all the environmental 
exposures that have previously been associated with schizophrenia spectrum disorders.  
Childhood adversity was assessed using the Childhood Trauma Questionnaire Short Form 
(CTQ)24. This consists of 28 items, rated on a 5-point Likert scale, measuring five domains of 
maltreatment (emotional and physical neglect; emotional, physical and sexual abuse). The 
psychometric characteristics of the translated versions (Spanish, Turkish, Dutch and Serbian) 
of the CTQ have been comprehensively studied25-27. To dichotomize each childhood adversity 
domain (0 = “absent” and 1 = “present”), consistent with previous work in the EUGEI28, we 
used the following cut-off scores for each domain: ≥9 for emotional abuse; ≥8 for physical 
abuse; ≥6 for sexual abuse; ≥10 for emotional neglect; and ≥8 for physical neglect.   
Cannabis use was assessed by a modified version of the Cannabis Experiences 
Questionnaire29 in the EUGEI (0 = “none”; 1 = “only once or twice”; 2 = “a few times a year”; 
3 = “a few times a month”; 4 = “once or more a week”; 5 = “everyday”), and by the L section 
of the Composite International Diagnostic Interview (CIDI)30 in the GROUP (0 = “none”; 1 = 
“less than weekly”; 2 = “weekly”; 3 = “daily”). Consistent with previous work31-33, a binary 
regular cannabis use variable was constructed by using the cut-off value of once or more per 
week during the lifetime period of most frequent use. 
In accordance with previous studies investigating the association between season of birth 
and schizophrenia in the Northern hemisphere sites34, the high-risk birth period was defined 
based on the winter solstice (December-March), and a binary winter-birth exposure was 
constructed.  
Hearing impairment was defined based on self-reported hearing impairment in the last 12 
months (0 = “absent” and 1 = “present”). 
The history of bullying by peers (emotional, psychological or physical violence) before 17 
years of age was assessed using the short version of the Retrospective Bullying Questionnaire 
(RBQ)35,36, that measures the severity of the bullying experience: 0 = “none”; 1 = “some (no 
physical injuries)”; 2 = “moderate (minor injuries or transient emotional reactions)”; 3 = 
“marked (severe and frequent physical or psychological harm)”. Exposure to childhood 
bullying was dichotomized using ≥1 as the cut-off point (0 = “absent” and ≥1 = “present”). 
 
Genetic data processing  
 
Samples of all individuals were genotyped at Cardiff University Institute of Psychological 
Medicine and Clinical Neurology, using custom Illumina HumanCoreExome-24 BeadChip 
genotyping arrays containing probes for 570038 genetic variants (Illumina, San Diego, CA). 
Genotype data were called using the GenomeStudio package and transferred into PLINK 
format for further analysis.  
Quality control was conducted in PLINK v1.0737 or with custom Perl scripts. Variants 
with call rate <98% were excluded from the dataset. Hardy-Weinberg equilibrium p-value was 
calculated separately in Turkish, Northern European and Southern European samples. Variants 
with Hardy-Weinberg equilibrium p-value <1e-6 in any of these three regions were excluded 
from the dataset. After quality control, 559505 variants remained. 
Samples with call rate <98% were excluded from the dataset. A linkage disequilibrium 
(LD) pruned set of variants was calculated using the --indep-pairwise command in PLINK 
(maximum r2 = 0.25, window size = 500 SNPs, window step size = 50 SNPs) and used for 
further analyses. Homozygosity F values were calculated using the --het command in PLINK, 
and outlier samples (F<–0.11 or F>0.15) were excluded. The genotypic sex of samples was 
calculated from X chromosome data using the --check-sex command in PLINK, and samples 
with different genotypic sex to their database sex were excluded. 
Identity-by-descent values were calculated for the sample in PLINK. Samples with one or 
more siblings among the genotyped samples according to the database but no identified 
genotypic siblings (defined as PI-HAT >0.35 and <0.65) were excluded. After these were 
removed from consideration, samples with two or more database siblings in the database that 
were not supported by the genotypic data were also excluded. 
After visually observing clustering of errors by genotyping chip, we decided to exclude 
chips with a high proportion of errors. All samples on chips with five or more sample 
exclusions due to heterozygosity or call rate (out of 12 possible samples) were excluded. All 
samples on chips with four or more sample exclusions due to sex or relative checks were also 
excluded, unless their identity was corroborated by concordance between database and 
genotype relatedness data with a sample on another chip. 
Principal components were calculated in PLINK using LD pruned variants after combining 
the dataset with the Thousand Genomes reference dataset. Due to the inherently multi-
population nature of the dataset and the variety of possible analyses, no exclusions were made 
to the whole dataset based on this analysis. Population effects were corrected for separately in 
individual analyses. 
After quality control, genotypes were imputed on the Michigan Imputation Server using 
the Haplotype Reference Consortium reference panel (version 1.1) and the programs Eagle for 
haplotype phasing and Minimac3 for imputation38,39. After imputation, variants with an 
imputation r2 >0.6, minor allele frequency (MAF) >0.1% and call rate >99% were retained 
(8277535 variants). Best-guess genotypes were generated from genotype probabilities using 
PLINK.  
PRS-SCZ was constructed using summary statistics from the Psychiatric Genomics 
Consortium genome-wide association study, excluding samples present in the GROUP data7. 
Clumping was performed in imputed best-guess genotypes for each dataset using PLINK 
(maximum r2 = 0.2, window size = 500kb, minimum MAF = 10%, minimum imputation 
information (INFO) score = 0.7), and variants within regions of long-range LD around the 
genome (including the human major histocompatibility complex) were excluded40. PRS-SCZ 
was then constructed from best-guess genotypes using PLINK at ten different p-value 
thresholds (1, 0.5, 0.3, 0.2, 0.1, 0.05, 0.01, 1x10-4, 1x10-6, 5x10-8). Consistent with previous 
research in the field41-44, we used p=0.05 for our primary analysis, as this threshold explained 
the most variation in the phenotype in the Psychiatric Genomics Consortium analysis7.  
To be able to compare our estimates from the current sample with the previously reported 
estimates of the proportion of variance explained by PRS-SCZ, a logistic regression model was 
applied to test the association of PRS-SCZ with case-control status (adjusted for ancestry using 
the first ten principal components), and Nagelkerke’s R2 was calculated. PRS-SCZ 
discriminated cases from controls (odds ratio, OR = 1.30; 95% CI: 1.25-1.34; p<0.001; 
Nagelkerke’s R2 = 0.15), after also controlling for age, sex and country (OR = 1.30; 95% CI: 
1.26-1.35; p<0.001; Nagelkerke’s R2 = 0.20). 
PRS-SCZ was dichotomized using the quartile cut-off points based on the control 
distribution of PRS-SCZ within each country (to account for differences in PRS-SCZ between 
countries that may arise due to ethnic variation). The highest quartile (PRS-SCZ > 75% of the 
controls) was considered the binary genetic risk state for schizophrenia (hereafter: PRS-SCZ75).  
 
Statistical analyses 
 
All analyses were carried out using the STATA version 15.045. Random intercept 
multilevel logistic regression models, taking into account clustering of participants within 
countries, were applied to test the univariate associations of exposures and PRS-SCZ75 with 
case status. For each exposure, gene-environment correlation was tested using multilevel 
logistic regression models in the control sample. To test gene-environment interaction, additive 
models were chosen over multiplicative models prior to data collection (EUGEI consortium 
meeting, December 14, 2013), because they provide superior representation of biological 
synergy46 and inform public health decisions within the sufficient cause framework47,48.  
To test the joint effects of environmental exposures and genetic score, we entered the four 
states occasioned by the combination of each exposure and binary PRS-SCZ risk state (PRS-
SCZ75) as independent variables (three dummy variables with no-risk state as the reference 
category), and case status as the dependent variable, in multilevel logistic regression models.  
We tested for departure from additivity using the interaction contrast ratio, also called the 
relative excess risk due to interaction (RERI). The RERI is considered the standard measure 
for interaction on the additive scale in case-control studies49. The RERI was estimated as 
(ORexposure&PRS-SCZ75 − ORexposure − ORPRS-SCZ75 + 1)50. A RERI greater than zero was defined 
as a positive deviation from additivity, and considered significant when the 95% CI of RERI 
did not contain zero. Using the ORs derived from each model, the RERIs for each model were 
calculated using the delta method.  
As a sensitivity measure, the alternative bootstrap percentile method51 (N=1,000 bootstrap 
replications) was applied to estimate the bootstrapped 95% CI for the RERI. All models were 
controlled for a priori covariates (age and sex), while models including PRS-SCZ75 were 
additionally adjusted for ancestry, using the first ten principal components accommodating to 
the general recommendations.  
The analyses were also conducted on imputed data, given missing observations in 
environmental exposure assessments. Under the assumption of missing at random, the multiple 
imputation chained equation model52 with 20 imputations restricted to in-range values was 
applied (relative efficiency ranging between 97% to 99%). Imputed data were similar to 
observed values in the original dataset. All analyses were run on multiply imputed data, and 
estimates were pooled using Rubin’s rules53.  
To test the robustness of our findings, sensitivity analyses of binary genetic risk thresholds 
were conducted using the PRS-SCZ cut points at 50% and 25% of the controls. The nominal 
significance threshold was set at p=0.05.  
 
 
RESULTS 
 
Data concerning age, sex and environmental exposures in cases and controls are reported 
in Table 1.  
All exposures except winter birth were associated with case status, also after adjusting for 
age and sex. Table 2 presents the unadjusted and adjusted ORs for PRS-SCZ75 and each of the 
exposures associated with case status.  
Except for physical abuse, there was no evidence for gene-environment correlation, as 
PRS-SCZ75 was not associated strongly or significantly with exposures in the control group 
(Table 3). Physical abuse was associated with PRS-SCZ75 (adjusted OR = 1.84; 95% CI: 1.19-
2.84; p=0.006). 
Table 4 reports the interactive effects of PRS-SCZ75 and the exposures on the case status. 
There was evidence for additive interaction between PRS-SCZ75 and regular cannabis use 
(RERI = 5.60; 95% CI: 0.88-10.33; p=0.020), childhood bullying (RERI = 2.76; 95% CI: 0.29-
5.23; p=0.028), emotional abuse (RERI = 5.52; 95% CI: 2.29-8.75; p<0.001), sexual abuse 
(RERI = 7.61; 95% CI: 2.05-13.17; p=0.007), and emotional neglect (RERI = 2.46; 95% CI: 
0.98-3.94; p=0.001), respectively. Figure 1 visualizes the significant interaction effects on an 
additive scale. No evidence was found for significant additive interaction effects between PRS-
SCZ75 and physical abuse, physical neglect, hearing impairment, and winter birth.  
Analyses using the alternative bootstrap percentile method for estimating additive 
interactions yielded similar results. The sensitivity analyses replacing the a priori set PRS-
SCZ75 as the genetic risk in the models with the alternative cut-points of PRS-SCZ (50% and 
25%) confirmed that additive interaction was evident for regular cannabis use, childhood 
bullying, emotional abuse, sexual abuse, and emotional neglect across all PRS-SCZ cut-points. 
The results from the analyses performed in the imputed data were similar (Table 5).   
 
DISCUSSION 
 
In this study examining the main and joint associations of environmental exposures and 
genetic liability with schizophrenia spectrum disorder, evidence emerged for a positive additive 
interaction of genetic liability with regular cannabis use and childhood adversity domains 
(sexual abuse, emotional abuse, emotional neglect, and childhood bullying).  
To the best of our knowledge, our study is the first to report that the sensitivity to adverse 
life events during childhood and exposure to cannabis is moderated by genetic risk state for 
schizophrenia (PRS-SCZ75). Put simply, the positive additive interaction between genetic 
liability and environmental exposure indicates synergy between gene and environment; that is, 
the combined influence of genetic liability and environmental exposure is larger than the sum 
of individual effects of each.  
In line with previous findings, PRS-SCZ75 discriminated cases from controls and all 
environmental exposures (except for winter birth) were associated with case status. However, 
no evidence for an additive interaction with PRS-SCZ75 was observed for physical abuse, 
physical neglect, hearing impairment, or winter birth.  
The proportion of variance explained by PRS-SCZ in our sample was comparable to 
previously reported estimates54 and the most recent findings from the Psychiatric Genomics 
Consortium7. In this dataset, we strictly conformed to previous definitions of environmental 
exposures to improve reproducibility and allow comparability. In agreement with previous 
reports, our univariate analysis demonstrated that the exposures we tested were associated with 
case status to varying degrees, that were similar to meta-analytical estimates12,13.  
By taking advantage of direct molecular measures of genetic risk, we provided further 
support for the putative role of gene-environment interaction in schizophrenia spectrum 
disorder that was observed in previous studies applying indirect genetic liability estimates 
derived from family-based (e.g., twin, relative) samples55. Our findings were corroborated by 
the results obtained from regression models using different genetic liability thresholds (PRS-
SCZ cut-offs at 50% and 25%) and analyses ran in imputed data. 
The RERIs and 95% CIs for emotional and sexual abuse were above 2, thereby suggesting 
a “mechanistic” interaction50, i.e., that there are individuals who would develop schizophrenia 
only when both genetic liability and environmental exposure (emotional or sexual abuse) are 
present, but would not develop schizophrenia when either genetic liability or environmental 
exposure is present alone.  
PRS-based approaches have recently gained traction in detecting gene-environment 
interaction. Previously, studies investigated the possible interaction between some genetic 
polymorphisms possibly linked to the putative biological mechanisms underlying psychosis 
and cannabis use or childhood adversity. Although SNPs (in various genes) for genetic 
moderation (e.g., AKT1, COMT, BDNF) were identified, these findings were inconsistent 
across samples56 and became secondary once the genome-wide approach took over the scene.  
To date, a limited number of studies tested gene-environment interaction across the 
psychosis spectrum using PRS-SCZ. A pilot study of 80 patients with first-episode psychotic 
disorders and 110 controls investigating whether PRS-SCZ moderates the association between 
childhood adversities and psychosis, although yielding main effects of both PRS-SCZ and 
childhood adversities, was considerably underpowered to detect gene-environment 
interaction57. A recent study demonstrated that intra-uterine environment moderates the 
association between PRS-SCZ and schizophrenia, and further revealed in the pathway analysis 
that genes involved in cellular stress response were the main drivers of the gene-environment 
interaction58. In our recent study of a general population twin cohort, we found evidence for 
positive interaction effects between PRS-SCZ and exposure to childhood adversities to 
pleiotropically influence momentary emotional regulation and psychosis proneness59. Further, 
a multimodal study combining genetics and imaging techniques reported that the association 
between PRS-SCZ and cortical maturation in young male adults is moderated by early-life 
exposure to cannabis60. Taken together, while the area of gene-environment research is 
progressing rapidly toward a more replicable path informed by the use of GWA data, 
conclusive evidence has yet to emerge.  
There are various ways in which our findings can move forward gene-environment 
interaction research in the GWA era. First, they are useful in providing direction for future pre-
registered confirmatory studies. Second, they may open up promising research lines for further 
exploration of gene-environment interactions in the biological context, such as using 
biologically-informative pathway scores instead of an aggregate genetic risk score for disease 
phenotype. These studies may help us investigate both hypotheses for biologically plausible 
pathways impacted by distinct exposures (e.g., hypoxia-ischemia pathway X obstetric 
complications and childhood adversities X hypothalamic-pituitary-adrenal axis)61,62, and 
putative common final pathways, such as the broad inflammatory pathway which may be 
influenced by many exposures cumulatively63. 
However, there are important caveats: pathway scores may be less powerful than the 
overall polygenic scores for phenotypes, and there are almost endless options for selecting and 
constructing “putative” pathways. Therefore, gene-sets for pathways should be a priori defined 
and frozen at a central repository to avoid data-dredging. Further, study protocols for 
hypothesis-driven selective exposure and pathway analyses (e.g., regular cannabis use and 
endocannabinoid pathway) should ideally be either registered, or, if this is not possible, 
agnostic data analyses should be followed through. 
 
In our study, data were collected through extensive interviews by trained psychiatrists, 
psychologists and research assistants to specifically test the role of gene-environment 
interaction in schizophrenia. Further, our culturally and geographically diverse sample 
provided us with the advantage of observing variations in environmental exposures, which 
increases the power to detect interaction effects64.  
However, some limitations should be acknowledged. First, the cross-sectional design 
informs only on temporal association and not causality. Nevertheless, cross-sectional analyses 
arguably remain an essential first step for identifying risk factors and pave the way for future 
longitudinal studies to investigate gene-environment interaction in evolutionary trajectories. 
Second, given the sample size and explorative nature of the study, we focused on main and 
interaction associations of previously established environmental factors and PRS-SCZ. 
However, the reality is much more complex than current statistical models can accommodate, 
involving dynamic interactions, causal and non-causal associations within the exposome – e.g., 
dense correlation matrix of environmental factors influenced by the timing, duration, severity 
and extent of repeated exposures over time16,65; the genome – e.g., epistasis (gene-gene 
interaction), redundancy (two or more genes perform the same function) and pleiotropy (the 
same gene contributes to two or more supposedly unrelated phenotypes)66; and the phenome 
(multidimensional syndromal diversity)67. Third, instead of the commonly-exercised selective 
reporting of one exposure at a time, we embraced a quasi-systematic approach to provide an 
overall picture of the gene-environment interactions findings from this dataset. However, we 
could not test some other known exposures (e.g., obstetric and pregnancy complications).  
In conclusion, by using a molecular genetic risk measure, we have provided further 
evidence for the role of gene-environment interaction in schizophrenia. Our findings warrant 
further validation in pre-registered confirmatory research. 
 
 
APPENDIX 
 
GROUP investigators in EUGEI included: Behrooz Z. Alizadeh, Therese van Amelsvoort, 
Nico J. van Beveren, Richard Bruggeman, Wiepke Cahn, Lieuwe de Haan, Philippe Delespaul, 
Jurjen J. Luykx, Inez Myin-Germeys, Ruud van Winkel and Jim van Os. 
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 Total Controls Cases Missing rates 
Age (years, 
mean±SD) 
  
32.4±9.8 
 
33.4±10.6 
 
31.5±9.0 
 
 
Sex     
   Male 1,951 (60.2%) 762 (49.4%) 1,189 (70.0%) 
 
   Female 1,290 (39.8%)  780 (50.6%) 510 (30.0%) 
Cannabis use      
   No 2,390 (78.6%) 1,366 (91.2%) 1,024 (66.5%) 
202 (6.2%) 
   Yes 649 (21.4%) 132 (8.8%) 517 (33.5%) 
Bullying      
    No 1,947 (72.3%) 1,101 (83.7%) 846 (61.4%) 
547 (16.9%) 
    Yes 747 (27.7%) 215 (16.3%) 532 (38.6%) 
Emotional abuse       
No 2,019 (73.0%) 1,230 (84.8%) 789 (60.0%) 
475 (14.7%) 
Yes 747 (27.0%) 221 (15.2%) 526 (40.0%) 
Physical abuse      
      No 2,477 (88.7%) 1,362 (93.0%) 1,115 (84.0%) 
450 (13.9%) 
      Yes 314 (11.3%) 102 (7.0%) 212 (16.0%) 
Sexual abuse     
       No 2,269 (81.5%) 1,309 (90.1%) 960 (72.1%) 
456 (14.1%) 
       Yes 516 (18.5%) 144 (9.9%) 372 (27.9%) 
Emotional neglect     
        No 1,254 (45.3%) 789 (54.3%) 465 (35.4%) 
473 (14.6%) 
        Yes 1,514 (54.7%) 664 (45.7%) 850 (64.6%) 
Physical neglect     
        No 1,804 (64.8%) 1039 (71.3%) 765 (57.7%) 
457 (14.1%) 
        Yes 980 (35.2%) 419 (28.7%) 561 (42.3%) 
Winter birth     
        No 1,989 (63.2%) 951 (63.0%) 1,038 (63.4%) 
94 (2.9%) 
        Yes 1,158 (36.8%) 559 (37.0%) 599 (36.6%) 
Hearing 
impairment  
    
Table 1  Demographic variables and environmental exposures in cases and controls 
 
 
 
  
        No 2,869 (92.5%) 1,437 (95.6%) 1,432 (89.7%) 
141 (4.4%) 
        Yes 231 (7.5%) 66 (4.4%) 165 (10.3%) 
Table 2  Main effects of environmental and genetic risk on case-control status 
 
 
 
PRS-SCZ75 – polygenic risk score for schizophrenia (75% cut-point) 
 aadjusted for sex and age, badjusted for ten principal components  
  
 Unadjusted main effects Adjusted main effectsa 
 Odds ratio (95% CI) p Odds ratio (95% CI) p 
Cannabis use  4.85 (3.89-6.05) <0.001 3.96 (3.16-4.97) <0.001 
Bullying 3.01 (2.48-3.65) <0.001 3.06 (2.50-3.74) <0.001 
Emotional abuse 3.51 (2.93-4.22) <0.001 3.77 (3.12-4.56) <0.001 
Physical abuse 2.70 (2.10-3.48) <0.001 2.83 (2.18-3.67) <0.001 
Sexual abuse 3.66 (2.96-4.53) <0.001 4.11 (3.30-5.13) <0.001 
Emotional neglect 2.52 (2.14-2.96) <0.001 2.65 (2.24-3.13) <0.001 
Physical neglect 2.32 (1.96-2.75) <0.001 2.33 (1.96-2.78) <0.001 
Winter birth 1.06 (0.92-1.23) 0.423 1.05 (0.91-1.23) 0.495 
Hearing impairment 2.46 (1.82-3.31) <0.001 2.67 (1.96-3.62) <0.001 
PRS-SCZ75b 2.91 (2.48-3.40) <0.001 2.85 (2.43-3.35) <0.001 
Table 3  Gene-environment correlation between PRS-SCZ75 and environmental exposures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRS-SCZ75 – polygenic risk score for schizophrenia (75% cut-point) 
 aadjusted for sex, age and ten principal components 
 
 Unadjusted effects Adjusted effectsa 
 Odds ratio (95% CI) p Odds ratio (95% CI) p 
Cannabis use 0.98 (0.61-1.59) 0.949 0.93 (0.57-1.52) 0.771 
Bullying 1.27 (0.86-1.86) 0.228 1.28 (0.87-1.89) 0.210 
Emotional abuse 1.13 (0.80-1.58) 0.493 1.13 (0.81-1.59) 0.476 
Physical abuse 1.82 (1.18-2.81) 0.007 1.84 (1.19-2.84) 0.006 
Sexual abuse 0.79 (0.51-1.22) 0.287 0.79 (0.51-1.23) 0.292 
Emotional neglect 1.18 (0.91-1.52) 0.212 1.16 (0.90-1.50) 0.258 
Physical neglect 1.18 (0.89-1.56) 0.246 1.19 (0.90-1.58) 0.219 
Winter birth 1.13 (0.88-1.45) 0.338 1.13 (0.88-1.45) 0.332 
Hearing impairment 1.13 (0.63-2.02) 0.693 1.18 (0.65-2.13) 0.592 
Table 4  Interaction of environmental exposures and PRS-SCZ75 on case-control status  
 
 PRS-SCZ75 = 0 PRS-SCZ75 = 1 
RERI (95% CI) 
 
N 
cases/controls 
Odds ratio (95% 
CI) 
N 
cases/controls 
Odds ratio (95% 
CI) 
Cannabis use = 0 556/1042 1.0 468/324 2.84 (2.36-3.40) 
p<0.001 
5.60  
(0.88-10.33) 
p=0.020 Cannabis use = 1 296/102 4.10 (3.13-5.36) 
p<0.001 
221/30 
11.54 (7.60-17.51) 
p<0.001 
Bullying = 0 454/842 1.0 392/259 
2.84 (2.31-3.47) 
p<0.001 
2.76 
 (0.29-5.23) 
p=0.028  Bullying = 1 296/163 
2.97 (2.34-3.76) 
p<0.001 
236/52 
7.56 (5.41-10.56) 
p<0.001 
Emotional abuse = 0 464/939 1.0 325/291 
2.39 (1.95-2.94) 
p<0.001 
5.52  
(2.29-8.75) 
p<0.001 Emotional abuse = 1 273/166 
3.26 (2.58-4.12) 
p<0.001 
253/55 
10.17 (7.33-14.10) 
p<0.001 
Physical abuse = 0 632/1049 1.0 483/313 
2.71 (2.25-3.26) 
p<0.001 
1.64  
(–1.07 to 4.34) 
Physical abuse = 1 107/65 
2.97 (2.11-4.17) 
p<0.001 
105/37 
6.31 (4.19-9.52) 
p<0.001 
p=0.235 
Sexual abuse = 0 536/993 1.0 424/316 
2.68 (2.21-3.25) 
p<0.001 
7.61  
(2.05-13.17) 
p=0.007 Sexual abuse = 1 208/114 
3.89 (2.99-5.08) 
p<0.001 
164/30 
13.19 (8.60-20.22) 
p<0.001 
Emotional neglect = 0 273/610 1.0 192/179 
2.64 (2.03-3.44) 
p<0.001 
2.46  
(0.98-3.94) 
p=0.001 Emotional neglect = 1 464/495 
2.58 (2.10-3.17) 
p<0.001 
386/169 
6.69 (5.20-8.59) 
p<0.001 
Physical neglect = 0 438/804 1.0 327/235 
2.81 (2.26-3.50) 
p<0.001 
1.51 
(0.00 to 3.03) 
p=0.051 Physical neglect =1 308/306 
2.42 (1.95 to 3.01) 
p<0.001 
253/113 
5.75 (4.36 to 7.58) 
p<0.001 
Winter birth = 0 562/733 1.0 476/218 
3.11 (2.53 to 3.82) 
p<0.001 
–0.55 
(–1.36 to 0.27) 
p=0.186 
Winter birth = 1 333/414 
1.16 (0.96 to 1.41) 
p=0.123 
266/145 
2.72 (2.14 to 3.48) 
p<0.001 
Hearing impairment = 0 767/1098 1.0 665/339 
2.97 (2.51 to 3.52) 
p<0.001 
1.04 
(–2.65 to 4.74) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hearing impairment = 1 107/50 
3.11 (2.16 to 4.48) 
p<0.001 
58/16 
6.13 (3.43 to 10.95) 
p<0.001 
p=0.579 
  
PRS-SCZ75 – polygenic risk score for schizophrenia (75% cut-point), RERI – relative excess risk due to interaction 
Data adjusted for sex, age and ten principal components    
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Figure 1  Additive effects of cannabis use, emotional abuse, sexual abuse, emotional neglect and bullying on 
the association between the polygenic risk score for schizophrenia, 75% cut-point (PRS) and case-control status, 
adjusted for sex, age and ten principal components; RERI – relative excess risk due to interaction 
  
Table 5  Additive interaction effects of PRS-SCZ75 and the environmental exposures on case-control 
status in the imputed data   
 
 
     Main effects      Interaction   
  Odds ratio (95% CI)  p RERI (95% CI)  p  
Cannabis use  3.94 (3.15-4.93) <0.001 5.18 (0.62-9.74) 0.026 
Bullying  2.88 (2.36-3.51) <0.001 2.88 (0.63-5.13) 0.012 
Emotional abuse  3.49 (2.88-4.24) <0.001 5.11 (2.10-8.13) 0.001 
Physical abuse  2.65 (2.06-3.40) <0.001 1.40 (–1.10 to 3.90) 0.272 
Sexual abuse  3.74 (3.00-4.66) <0.001 6.84 (1.77-11.92) 0.008 
Emotional neglect  2.51 (2.14-2.95) <0.001 2.37 (0.90-3.84) 0.002 
Physical neglect  2.14 (1.79-2.57) <0.001 1.42 (–0.05 to 2.88) 0.058 
Winter birth  1.06 (0.91-1.23) 0.485 -0.53 (–1.36 to 0.30) 0.209 
Hearing impairment  2.68 (1.97-3.66) <0.001 1.24 (–2.51 to 5.00) 0.516 
 
 
PRS-SCZ75 – polygenic risk score for schizophrenia (75% cut-point), RERI – relative excess risk due to 
interaction 
Data adjusted for sex, age and ten principal components   
 
